Donaperminogene seltoplasmid

Unassigned

New Medicines

Painful diabetic peripheral neuropathies (PDPN)

Information

Advanced therapy medicinal product (ATMP) (gene therapy)
Helixmith
Helixmith

Development and Regulatory status

None
None
Phase III Clinical Trials

Category

First-in-class non-viral plasmid DNA gene therapy which aims to restore blood flow to affected areas through regenerative angiogenesis. Aids formation of new microvasculature and re-myelination and regeneration of damaged nerves.[2,3]
In England, ~1 in 10 people aged 45-54 years have type 2 diabetes and about 1 in 4 people aged >75 years have it. Persistent painful neuropathy affects up to 1 in 4 people with type 2 diabetes. Over 50% of pts with type 2 diabetes aged >60 yrs have peripheral neuropathy. Around 1 in 300 people develop type 1 diabetes and type 1 diabetics usually develop neuropathy after >10 years of living with the condition. [1-3]
Painful diabetic peripheral neuropathies (PDPN)
Intramuscular